A clinical trial management system (CTMS) is the software that runs the operational side of a clinical trial. It shows which sites are open, how many patients are enrolled, which visits took place, which monitoring reports are due and where each study stands against plan. Sponsors use a CTMS to oversee their studies and their CROs. CROs use one to deliver studies for many sponsors at once. Sites and academic centers use one to manage calendars, visits and billing.
A CTMS is not an EDC. The EDC (electronic data capture) holds the clinical data, so what was measured in each patient. The eTMF (electronic trial master file) holds the documents an inspector will ask for. The CTMS holds the operational data in between. Most organizations run all three, from one vendor or from several.
What changed for 2027 is less the core of a CTMS and more what surrounds it:
AI moved into the budget. In a 2026 survey of 200 senior leaders at pharma, biotech and CRO organizations, 92% plan to spend more on AI. Only 29% say it has met their expectations so far (Medidata and Everest Group, 2026).
Regulators raised the bar on oversight. ICH E6(R3) has applied in the EU since July 2025 and expects sponsors to oversee the work they outsource. Its Annex 2 on decentralized elements, pragmatic designs and real-world data takes effect in the EU on 15 January 2027 (CITI Program, 2026).
The money got tighter. A third of listed biotechs ended 2025 with less than a year of cash (EY via BioSpace, 2026). Every amendment, every late site and every surprise invoice now shows up in the runway.
This guide covers the four types of CTMS, the eight criteria a system needs to meet in 2027 and the systems that fit each need best.
The four types of CTMS, and what each one sees of the money
Not every CTMS is built for the same job. Four types cover most of the market.
Type | What it sees of the money |
|---|---|
Enterprise full-suite CTMS Built for: Oversight of studies across countries and CROs Typical users: Large sponsors, global CROs | Milestones and site payments, often in add-on modules. Budgets and forecasts often sit in other tools |
Unified eClinical platform Built for: CTMS on the same data model as EDC, eTMF and RTSM Typical users: Sponsors and CROs that want one vendor | Operational and clinical data in one place. Budgets and forecasts often sit outside |
Site CTMS Built for: Calendars, visits, patient stipends and sponsor invoicing Typical users: Research sites, site networks, academic centers | The site’s own billing and receivables |
Financial CTMS (financial suite) Built for: Budgets, quotes, amendments, CRO and vendor costs, invoices, accruals and forecasts Typical users: Sponsor finance, CRO finance and project managers | The whole trial budget: plan, actuals, versions and forecast |
Most CTMS handle sites, visits, milestones and documents well. The money is a different story. Budgets, site contracts, amendments, CRO invoices and forecasts often live in spreadsheets next to the CTMS. Finance teams and project managers maintain them, and many of them never log into the CTMS at all.
That gap is why the fourth type exists. A financial CTMS doesn’t replace the operational one. It runs next to it and turns operational data into what finance and management need: plan vs actual, forecast and cash.
Ownership matters too. Many small and mid-sized sponsors rely on their CRO’s systems. Veeva argues that sponsors should own their CTMS for the sake of oversight (Veeva, 2026). That is a vendor’s argument, but the oversight point holds for the money as well. If your only view of the budget is the CRO’s invoices, you see it late.
The eight criteria for a CTMS in 2027
Each criterion comes with a verdict: must-have in 2027 or nice to have. Use them as a checklist.
1. AI and automation, with governance
Verdict: must-have, but only with an audit trail and human review.
AI in a CTMS should take work off people: drafting reports, importing and mapping data, flagging deviations and answering questions about a study. Workflows are where it works best so far. In the same 2026 survey, 46.5% report better-than-expected results for task and workflow automation, against 29% for AI overall.
Governance is the other half. The EMA and the FDA published shared principles for good AI practice in medicine development in January 2026 (EMA, 2026). In April 2026 the FDA issued a warning letter to a manufacturer whose AI tools wrote GMP documents that went into use without review by its quality unit (Quality Magazine, 2026). That case is about manufacturing, but the lesson carries over to any GxP record: an AI output needs a person who approves it.
Ask the vendor:
Which tasks does the AI do today, and what evidence do you have for them?
Is every AI action logged with input, output, user and time?
Can a person approve before anything is written to the record?
Where does the model run, and is our data used for training?
2. Collaboration across sponsor, CRO and sites
Verdict: must-have.
A trial is run by at least three organizations, and the CTMS is where they should meet. Today sites carry most of the system load. 37% of sites use three to four study-specific systems per active trial, and some report up to 18 systems for a single study (Florence survey via Clinical Tech Leader, 2026).
In 2027 a CTMS should let CROs, vendors and sites work in it with their own roles. Approving a budget, a change order or a monitoring report should happen in the system with an audit trail, not in email threads with attachments.
Ask: Can external partners work in the system with their own roles? Which approvals run inside the system?
3. Integration and APIs
Verdict: must-have.
No CTMS does everything, so it has to exchange data well. The usual neighbours are the EDC for enrollment and visits, the eTMF for documents, RTSM or IRT for randomization and supply, the safety database, the finance system and your BI tools.
Ask for a documented API, standard exports and connectors that already run in production with the systems you use. Also ask about structured protocols. ICH M11, adopted in November 2025, makes protocols machine-readable (BioXconomy). A system that reads a structured protocol can set up the visit schedule, and the budget grid behind it, without anyone retyping it.
Ask: Which connectors run in production today? Is the API documented and included in the license?
4. Financial management
Verdict: must-have, and the criterion most CTMS evaluations underweight.
Clinical trial budgets used to be a finance topic. In 2027 they decide whether a study starts on time and whether it can be finished.
Amendments are the norm. Three in four protocols (75.8%) now get at least one amendment, against 57% in the Tufts study from 2016. Each amendment changes site fees, the CRO’s scope and the timeline (Getz et al., 2024; Getz et al., 2016).
Money ends trials too. Of the new drugs that entered Phase III between 1998 and 2008 and then failed, 22% failed for commercial reasons rather than for safety or efficacy (Hwang et al., 2016).
Negotiation delays the start. Budget negotiation is now the top reason sites start late (WCG, 2026), and sites turn down contracts whose budgets they can’t accept.
Pass-throughs escape control. CRO pass-through costs are a large part of the bill and get reconciled late. Our article on CRO pass-through costs shows how to control them.
What a CTMS needs to cover for the money:
Budgets calculated from trial parameters such as countries, sites, patients, visits and procedures, from the ballpark budget to the final quote
Amendments as budget versions, with the difference visible
Site budgets per site, with payment terms, holdbacks and screen-failure rules
CRO and vendor budgets including pass-through costs, tracked against invoices
Plan vs actual and a monthly forecast for each study and for the portfolio
Accruals that finance can book without rebuilding them in a spreadsheet
Scenarios: what happens to cost and cash if enrollment slips by three months?
Ask: Does the system calculate a budget or only store one? What happens to the budget when an amendment is approved? Can finance get monthly accruals out of it?
5. Compliance
Verdict: must-have, and table stakes for every serious vendor.
The basics haven’t changed: 21 CFR Part 11 for electronic records and signatures, a complete audit trail, validation documentation and GDPR for European data. In the EU, the EMA guideline on computerised systems and electronic data in clinical trials sets the expectations for systems like a CTMS.
What’s new is the scope. ICH E6(R3) asks for risk-proportionate quality management and clear sponsor oversight of service providers. Annex 2 adds decentralized elements such as home visits, remote assessments and direct-to-patient supply. Your CTMS should be able to track activities that no longer happen at a site.
Ask: What does the vendor’s validation package contain? Can you export the full audit trail, including AI actions?
6. Usability and site burden
Verdict: must-have. Test it with your own users.
A CTMS is only as good as the data people put into it, and people only keep a system up to date if it saves them time. So don’t judge usability from a demo. Ask for a sandbox and run three everyday tasks with the people who will do them: a CRA logging a visit, a project manager updating a milestone and a finance user checking plan vs actual.
Count the clicks and the workarounds. Check mobile access for CRAs and how much a site has to enter twice.
7. Deployment and security
Verdict: must-have. Read the certificates closely.
Cloud is the default in 2027. Check where the data is hosted (EU hosting is often required for EU trials), single sign-on, role-based access, encryption, backups and the exit: how you get all your data out when you leave.
Ask what each certificate covers. ISO 27001 or SOC 2 can apply to the vendor’s organization, to the product or to the hosting environment. All of them are useful, but they are different promises.
8. Pricing transparency
Verdict: nice to have, and it saves money. Ask before you sign.
We don’t list vendor prices here. They change, and they depend on scope. What you can do is ask the questions that show the total cost:
What is the license model: per study, per user, per site or enterprise?
What do implementation, validation and integrations cost?
Are AI features included, or priced on top of the license?
Do CRO and site users need paid licenses?
What do data migration and the exit cost?
How are price increases handled at renewal?
Ask for the total cost over three years. It is the only number that compares vendors fairly.
The financial suite CTMS: where Trialytix fits
Trialytix is the financial suite CTMS. It covers criterion four in depth and leaves the operational core, from site management to monitoring and documents, to the CTMS you already run or plan to buy. It complements that system instead of replacing it.
Budgeting. Trialytix calculates clinical trial budgets from trial parameters such as sites, patients, phases and timelines, from the ballpark budget through the quote to every amendment.
Study controlling. Plan vs actual, forecasts and early warnings when a budget drifts. Milestones carry their status, Open or Invoiced, and CRO and vendor invoices are tracked against the plan next to a liquidity forecast.
AI automation. Automated workflows connect Trialytix with CTMS exports, spreadsheets and finance tools. They import and map data, recognize uploaded invoices, build reports and flag deviations, with validation and controlled execution.
The result is one shared truth. Clinical operations, finance and management look at the same budget, the same versions and the same forecast. Scenarios and approvals happen in one place instead of in three budget versions across three spreadsheets.
See the Sponsor Suite, the CRO Suite and AI Automation.
Which CTMS fits which need
How we picked. We used public product information as of November 2026 and the eight criteria above. No vendor paid for a mention. Trialytix is our own product, and we name it only where it is built for the job.
If you need | Look at |
|---|---|
Oversight of a global portfolio across CROs | Veeva Vault CTMS Strongest on collaboration and integration within Veeva’s clinical platform |
One platform from EDC to CTMS | Medidata CTMS Strongest on integration with Rave EDC on a shared data model |
Document exchange between sites and sponsors | Florence Strongest on collaboration on site documents, next to a CTMS |
Oversight of CROs and vendors, as ICH E6(R3) expects | Mayet VendorVigilance Strongest on vendor oversight from selection to study closure |
Budgets, amendments, CRO invoices and forecasts | Trialytix Strongest on financial management |
AI automation across systems | Trialytix, Veeva, Medidata Strongest on AI with governance |
Want a ranked list of vendors? Read our overview of the best CTMS software.
How to choose a CTMS for your organization
Large sponsors. An enterprise CTMS for oversight across CROs and countries. If finance still runs trial budgets in spreadsheets, add a financial CTMS and connect both to your ERP.
Small and mid-sized biotechs. If your CRO runs the operational CTMS, start with your own view of the money and with oversight reports: budget, CRO invoices, pass-through costs, forecast and cash runway. Add an operational CTMS when you run more studies in-house.
CROs. An operational CTMS to deliver studies, plus a financial system for quotes, budgets, change orders and the margin of each study.
Sites and site networks. A site CTMS for calendars, visits, patient stipends and sponsor invoicing.
Academic centers. An academic CTMS for protocols and compliance, plus budgets that track every funding source.
Whatever your type, start with your three biggest problems and score each vendor against them.
How to run a CTMS evaluation
Write down problems, not features. Ask three groups: clinical operations, finance and your partners at the CRO and the sites. Three problems from each group are enough.
Pick the type first. Decide which of the four types you need, and whether you need one or two. That cuts the shortlist to three or four vendors.
Send your own study. Give every vendor the same anonymized study: a protocol synopsis, countries, sites, the visit schedule and one amendment. Ask them to show it in their system instead of running a standard demo.
Test in a sandbox. Spend two weeks with the people who will use the system, on the three everyday tasks from criterion six.
Call references of your size. A reference from a top-20 sponsor tells a 30-person biotech very little.
Compare the total cost over three years. License, implementation, validation, integrations, AI add-ons, external users and the exit.
The study you send in step three does most of the work. Within an hour you see whether a system can handle your visit schedule, your amendment and your budget.
Where the CTMS is heading
Our prediction, to check in the 2028 edition: by the end of 2027, the large CTMS vendors will market budget forecasting or an AI agent for trial finance as part of their CTMS, and the top-ranking CTMS buyer guides will score financial management as a criterion of its own. The reason is simple. Trial money got tight, and the CTMS is where the operational data already sits.
FAQ
What is a CTMS?
A clinical trial management system (CTMS) is software for the operational management of clinical trials. It tracks sites, enrollment, visits, monitoring, milestones and documents, so sponsors, CROs and sites can see where each study stands against plan.
What are the key requirements for a CTMS in 2027?
Eight criteria matter: AI and automation with governance, collaboration across sponsor, CRO and sites, integration and APIs, financial management, compliance, usability and site burden, deployment and security, and pricing transparency. Financial management is the one most evaluations underweight.
What are the types of CTMS?
There are four main types: enterprise full-suite CTMS for large sponsors and CROs, unified eClinical platforms that combine a CTMS with EDC and eTMF, site CTMS for research sites and academic centers, and financial CTMS for budgets, amendments, invoices and forecasts.
Who uses a CTMS?
Sponsors use a CTMS to oversee their studies and CROs. CROs use one to deliver studies for many sponsors. Research sites, site networks and academic medical centers use one for calendars, visits and billing.
Does a CTMS manage clinical trial budgets?
Most CTMS track milestones and some handle site payments, but few calculate budgets, version amendments or forecast cost and cash. That is the job of a financial CTMS such as Trialytix, which runs next to the operational CTMS.
Is AI a must-have in a CTMS in 2027?
For workflow automation and drafting, yes, but only with an audit trail and human review. Ask the vendor for evidence on your own use case: in a 2026 survey only 29% of sponsor and CRO leaders said AI had met their expectations.
What is the difference between a CTMS and an EDC?
An EDC captures the clinical data of each patient. A CTMS manages the operational side of the trial: sites, enrollment, visits, monitoring and milestones. The two exchange data, and many vendors offer both.
What does a CTMS cost?
It depends on the license model (per study, user, site or enterprise), on implementation, validation and integrations, and on add-ons such as AI. Compare vendors on the total cost over three years, including external users and exit costs.
Sources
Medidata and Everest Group, How is AI being used in clinical trials? 5 key statistics for 2026, Jun 2026 and the survey release, May 2026 (vendor-commissioned, 200 respondents)
Veeva, Justifying the strategic necessity of CTMS ownership, Jul 2026 (vendor)
EMA and FDA, common principles for AI in medicine development, Jan 2026
Getz et al., New Benchmarks on Protocol Amendment Practices, 2024
Getz et al., The Impact of Protocol Amendments on Clinical Trial Performance and Cost, 2016
Mayet, VendorVigilance, vendor oversight software for pharma and biotech sponsors (vendor)
